C-CHHWChronos Therapeutics
orexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-CHHW
C-CHHWC-CHHWorexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Chronos Therapeutics orexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
TheraCryf plc is a clinical stage therapeutics company developing therapeutics in behavioural brain disorders. Its pipeline includes an orexin-1 receptor antagonist for substance use disorders and anxiety, an atypical dopamine transporter inhibitor for fatigue and narcolepsy, and SFX-01 for glioblastoma. The company aims to generate compelling data sets and partner programmes with mid-size to large pharma.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Chronos Therapeutics — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic